725 related articles for article (PubMed ID: 23912973)
1. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
Shimosawa T
Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
[TBL] [Abstract][Full Text] [Related]
2. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
Black HR
Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
4. Drug therapy for the patient with resistant hypertension.
Donazzan L; Ewen S; Papademetriou V; Linicus Y; Linz D; Böhm M; Mahfoud F
Future Cardiol; 2015 Mar; 11(2):191-202. PubMed ID: 25760878
[TBL] [Abstract][Full Text] [Related]
5. Depressor effect of chymase inhibitor in mice with high salt-induced moderate hypertension.
Devarajan S; Yahiro E; Uehara Y; Habe S; Nishiyama A; Miura S; Saku K; Urata H
Am J Physiol Heart Circ Physiol; 2015 Dec; 309(11):H1987-96. PubMed ID: 26432844
[TBL] [Abstract][Full Text] [Related]
6. Control of vascular changes by renin-angiotensin-aldosterone system in salt-sensitive hypertension.
Zeng ZH; Luo BH; Gao YJ; Su CJ; He CC; Yi JJ; Li N; Lee RM
Eur J Pharmacol; 2004 Oct; 503(1-3):129-33. PubMed ID: 15496307
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
Sato A; Saruta T; Funder JW
Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
[TBL] [Abstract][Full Text] [Related]
8. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
9. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure.
Laragh JH; Sealey JE
Am J Hypertens; 2011 Nov; 24(11):1164-80. PubMed ID: 21938070
[TBL] [Abstract][Full Text] [Related]
10. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
11. Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage?
Lazich I; Bakris GL
Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):471-5. PubMed ID: 21709549
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin receptor blockers for management of hypertension.
Catanzaro DF; Frishman WH
South Med J; 2010 Jul; 103(7):669-73. PubMed ID: 20531060
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
15. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure reduction is not the only determinant of outcome.
Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR; Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR
Circulation; 2006 Jun; 113(23):2754-72; discussion 2773-4. PubMed ID: 16769926
[No Abstract] [Full Text] [Related]
17. Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.
Sim JJ; Bhandari SK; Shi J; Kalantar-Zadeh K; Rasgon SA; Sealey JE; Laragh JH
Am J Hypertens; 2012 Mar; 25(3):379-88. PubMed ID: 22158065
[TBL] [Abstract][Full Text] [Related]
18. Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Kujal P; Chábová VČ; Vernerová Z; Walkowska A; Kompanowska-Jezierska E; Sadowski J; Vaňourková Z; Husková Z; Opočenský M; Skaroupková P; Schejbalová S; Kramer HJ; Rakušan D; Malý J; Netuka I; Vaněčková I; Kopkan L; Cervenka L
Clin Exp Pharmacol Physiol; 2010 Dec; 37(12):1159-69. PubMed ID: 20880190
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.
Susic D; Varagic J; Frohlich ED
Am J Physiol Heart Circ Physiol; 2010 Apr; 298(4):H1177-81. PubMed ID: 20118410
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
